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Although prrcaieamide may markedly impair nr abolish antero-
grade
conduction over an accessory atrionentrirular IAVI path-
way, arthodrmnfc AV reentry may remain indueihle . This dill
ewe may be related to a systemic differential effect of
procalaamide on anterograde and retrograde accessory pathway
refiadtmness . To examine Ibis pliamormenam. an Infusion, or
proralnamidr producing Hoe ; rserenanbt blood tenets over 7S min
was administered to 15 patients with the Wolff•Parkinmn-White
syndrome. At each procainamde level, accessory Pathway Were-
Me refractory period and accessory pathway block cycle length
wen determined in the anterograde and retrograde directions .
At baseline, there were no significant differences helwnn
anterograde ad retrograde accessory pathway effective refner,
tory periods (282 ± 7 vs. 266 t 9 ms, p = 0 .08) slid block cycle
lengths (28112 15 vs. 283 ± 9 ms, p = 0.66) . The concentration of
proratnamfde resulting in 50% prolongation of accessory pathway
refractoriness was Into in the anterograde direction than in the
retrograde direction (27 .S [log concentration -4
.56 ± SE 0 .131 on.
Procainamide may impair or abolish anterograde conduction
over accessory atrioventricutar (AV) pathways, diminishing
the ventricular response during atrial fibrillation (1-3). De-
spite a favorable effect on anterograde conduction, orthu-
dromic AV reentry may still be easily inducible, suggesting
that the effects of procainamide on anterograde and retro-
grade accessory pathway refraclollness are distinct (2-41 .
Previous reports (4,5) suggest that procainamide has a sys-
tematic differential effect on the accessory pathway, pro-
longing anterograde accessory pathway rrfracloriness to a
greater extent khan retrograde accessory pathway refracto-
riness, To examine Ikis hypothesis . 15 patients with the
Wolff-Parkinson-White syndrome were studied . Antero-
grade and retrograde accessory pathway refractoriness was
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64.61-4.19 e: 0.1 11 µntalititer, p = 0.02). Similarly. the cancea-
tration of procaiamide resulting In 50% ptoklngkion i t seemy
sory pathway black cycle length in the anerograde direction (25 .1
1-4
.60 t 0.131 pnol1iter) was less than the retrograde
direction (52,5 1-4.28 s 0 .071 pmdNhr, p = 0.01) .
The probability of persistence o accessory pathway conduction
in the aneengrsde direction was lees than (n the retrograde
direction by tfaptan•M eler mall (p = 0.04) . By the 3rd
procainmide dose (area pracabamide level 32.3 * 1.36 anon
liter) anterograde pre-cxMtatlen was so longer present (n 6 ofme
15 patients, whereas retrograde conduction over the accessory
pathway did not disappear in any patient . These cantos demva-
strate that proeateamide has mare manliest elects an meregade
than an retrograde accessory pathway refraclorilxa . Thus, it
may be more elllcactoos for arrhy1hndas dependent en intern.
grade accessory pathway connection than For arrhythnws depen-
dent on rrogade accessory pathway cnndavtba .
(J Am Cog CarAW J01;10,1111-24)
assessed in the drug-free state and after five incremental
intravenous doses of procainamide.
Methods
Study patients. Consecutive patients with a single acces-
sory pathway undergoing clectlaphysiologic testing were
considered fur entry into the study . To ensure adequate
bidirectional conduction at baseline . patients were excluded
if the accessory pathway block cycle length was >450 ms in
either the anterograde or the retrograde direction . Other
exclusion criteria were retrograde accessory pathway con-
duction that was not clearly distinguishable from conduction
ever the normal ventriculeatrial conducting system, sus-
tained atriel fibrillation during the electropttysiologic study
and contraindications to procainamide administration- This
study was approved by the Review Board for Human Health
Sciences of the University of Western Ontario on May 17,
1990 and all patients gave written informed consent- Fifteen
patients with the Wolff-Parkinson-While syndrome and a
history of symptomatic techycardia were studied . There
were I I men and 4 women, with a mean age of 36 -_ 4 years .
Electrophysialogic study . Medications were discontinued
for >-5 half-lives before the elcctruphysiologic study . Two
0115-195T92a53 .50
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Figure 1 . Diagram of the procainamide
infusion protocol. Proeainamode onus
given as bolus iryeotions (omlkot ar-
rawr)in addition 16
a continuous Info
.
lion . The infusion rate was adjusted
	
9
and further bolus dunes given every
15 min
. Electrophysiulugic measure-
ments were made during the last S min
of each or the 15-min infusion periods .
+9 ,r
quadripoli r and one tripolar catheter were introduced into
the right femoral vein and positioned in the high right atrium,
right ventricular apex and [its bundle recording position,
respectively. An octapolar catheter was introduced into the
left subclavian vein and positioned in the coronary sinus .
Intracardiac electrograms were recorded simultaneously
with Surface electrocardiographic leads L 11 . 111, V, and V,
on a Siemer:s mingograph at a paper speed of 1110 mm/s
.
Programmed stimulation was performed at twice diastolic
threshold with 2-ms square wave pulses .
Anterograde and retrograde accessory pathway effective
refractory periods were Jeasured by the erlras6alufus teek-
nique at a drive cycle length of 4011 ms (5YI0 ms in two
patients) with 10-ms decrements in the S,S 2 coupling inter-
val . Anterograde accessory pathway refractory period was
defined as the longest A 1 A2 interval that failed to conduct
over the accessory pathway . The A,A, interval was mea-
sured on tae atrial electrogtam closest to the accessory
pathway as determined by mapping of retrograde atrial
activation during orthadromic AV tachycardia . The retro-
grade accessory pathway refractory period was defined as
the longest V,V,_ interval that failed to conduct over the
accessory pathway and was measured on the right ventric-
ular electrogram . The coronary sinus eleelrogram was not
used to measure the V 1 V 2 interval because the ventricular
electrogram at this site is frequently far field and does not
display an intrinsic deflection . Refractory period measure-
ments were made at the same site throughout the siuty . The
longest paced atria] and ventricular cycle lengths failing to
conduct over the accessory pathway (accessory pathway
block cycle lengths) were determined using lu-ms decre-
rncnts to a minimal cycle length of 250 ms. If atrial or
ventricular refractoriness limited the measurement of accts-
refractoriness
was used as an approximation . Similarly,
when 1 :1 conduction aver the accessory pathway persisted
to a cycle length of 250 ms
. this latter value was used as the
accessory pathway block cycle length .
Sludy prolecal . The procainamide infusion was begun
after control accessory pathway measurements Wig. 1).
Bolus doses of procainamide were given at the star of the
GM'rW ewittielftama)
W
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infusion and thereafter at I5-min intervals
. The initial infu-
sion rate of 7.5 mglmin increased every 15 min, doubling
with the first two increments and increasing by 50% with the
final two increments . The total duration of the infusion was
75 min and the total dose of procatnamide was 3,265 .5 mg.
At each measurement period, anterograde and retrograde
accessory pathway effective refractory period and block
cycle length were determined . Atria) pacing was performed
first in eight patients and ventricular pacing first in seven
patients . Blood procainamide levels were measured at the
start and finish of each electrophysiologic measurement
period. Because the difference (mean di(lecence 0,68 t 0.58
pmol!liler) between procainamide levels before and after
each measurement period was not significantly different
from zero, the mean of these two measurements was used
°nr analysis. Blood pressure was measured with an attn cuff
every 10 nlin and at the end of each electrophysielagic
measursmcntperiod . The study was termirat_d if symptoms
of toxicity occurred or the systolic blood pressure decreased
to <911 mm Hg.
Dais analyst, The effect of procainamide on the acres .
spry pathway was analyzed as follows
. Absolute changes in
accessory pathway variables were compared with repeated
measures analysis of variance (6). Measures at baseline were
compared with paired r tests. Second, the concentrations of
procainamide resulting in 508 proiongattan of refractoriness
and block cycle length (ECw
)
were calculated by using
nonlinear curve-fitting methods (sigmoid plot subroutine,
Graphpad program, ISI) (Fig. 2). Because measures of
potency demonstrate a ag-normal distribution (7), ECm was
expressed as geometric mean values with a range of ± I SE-
Comparisons of log EC ro measurements were made with
paired t tests. Finally, the probability of persistence of
accessory pathway conduction in the anterograde and retro-
grade directions duriugprocainamide infusion was estimated
by the Kaplan-Meier product lime melhod
. Comparison
between anterograde and retrograde conduction was then
performed with the generalized Wilcoxon test (8)
.
All p
values were two-tailed and were considered significant at a
level of0-o5 . Apart from EC sn, all other continuous variables
were reposed as arithmetic mean ± SE .
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Figere 2
. Patient 10 . Curve modeling of the proporlional change is
retrograde accessory pathway effective refractory period . To deter-
mine the concentration of procainamide resulting in 50% probnga
.
lion of accessory pathway nfracloriness IEC> o
1
. the (allowing
assumptions were made : 1) The maximal acressory pathway en'ec-
live refractory period was considered to be equal to the sinus cycle
length because changes greater than the sinus cycle length could not
be measured. 2) By this reasoning . control measurements of acces-
sory pathway refractoriness were considered to represent zero
prolongation of refractoriness and sinus cycle length to represent
100% prolongation of refrectoriness . 3) The percent prolongation of
accessory pathway refractoriness at each drug level was thus
dcacribed by the ratio (ERP4 ERP~(ISCL-ERPj . where ERPu
and ERP, arc, respe :lively, the accessory pathway refractory
period at the drug level and in the control period and SCL is the
sinus cycle length at the time of measurement . A similar analysis
was performed for accessory pathway block cycle length . Dose-
response curves wen calculated by using nonlinear cunofming
methods. The EC„ value for retrograde accessory pathway effec
live refractory period in this patient was 35.5 pmolltiter.
Table 1 . Control Accessory Pathway Measurements and Effects of Intravenous Procainamide in 15 Patients
P . 0.08 p = 0.66
[ACC Cot . 19 . No, I
ra..ary 199E-111-54
Results
Baseline stwllea. The accessory pathway was located in
the left lateral AV anulus in 13 of the 15 patients and in the
left pesteraseptal AV anulus in 2 patients. At baseline
. the
anterograde accessory pathway effective refractory period
was tot significaally different from the retrograde accessory
pathway effective refractory period (282 :t 7 vs . 266 ! 9 ms.
respectively, p = 0.08) (Table I) . Exact measurements of
accessory yathway refractory period in the anterograde
direction were made in 13 patients and in the retrograde
direction in II patients. There was no difference in the
shortest cycle length maintaining 1 :1 conduction over the
accessory pathway in the anterograde and retrograde direc-
tions (288 * 15 vs . 283 s 9 ms, p = 0.66). In nine patients .
exact measurements could be made anterogradely and ref-
rogradely.
Mean procainamide concentration during the procailro
mide infusion is shown in Figure 3 .
During the infusion,
there were significant dose-dependent decreases in
mean
blood pressure (P < 0.101) and sinus cycle length (p < 0 .001)
(Fig . 4)
. In four patients, the study was terminated before
completion of the fifth procainamide dose level either be-
cause of complete anterugtade and retrograde accessory
pathway block (Iwo patients) or because symptoms of tox-
icity with hypolension occurred (two patients) . The cuma-
Iative dose of procaummide given ranged from 26 .7 to
52.8 mglkg (mean 39.9 ±
2 .1),
Fdects of proeilna lde on Me pceemm y ralktray. Abso-
lute changes in accessory pathway effective refractory pe-
riod and black cycle length during the infusion are shown in
p=0.02 P-o .nl
AECL=auterepdeacaarayy
.rhwayblockcyckkngrh :AERP=eulemnsadeea'adivernranoyperiod :EC,,=conccmrafanotpc
.e,ie,ewki,gin
Hn6 probngatioO of-,A: w = sent; RECL = retrograde accessory pathway Noel cycle knelt : RERP - rewptde nrri., rc6.nmy p ,,d.
pt
No.
CaotrulMcawremcnts
Log
ECw AERP
tar
EC„ REAP
Log
EC,o ARCL
I-11
EC, ROLL
AERP RERP ABCL
RRCL
I 260 260 250 761 1 .31 t.7 1 .3 1 .78
2 300 310 410 290 1 .17 1.48
III
1 .47
3 6290 5230 <250 <2F0
4 260 285 260 720 103 1.61 1.88 1-9
5 2n 265 30D 20) 0.77 1 .66 0-73 1.64
6 260 270 <256 <250
7
320 320
420
3+0
.98 L55
0.75 1.53
R s270
.24n <25D 5250 156 -
1 .49 -
S
340
<_250
290
Sw
10 280 280 275 3110 1 .54 1 .55 1 .62 1 .48
11 310 320
340 761
1
.1 1
.42
1 .1
1
.39
12 275 <220 260
. 5
1 .26 1 .91 1
.26
1 .62
13 275
240 <240
<2A 2.51
2 .135 2.33 2 .13
14 260 220 <250 280 1.47 2 .74
1,44 2 .03
Is 270 270 <250 <250 1 .74 2.06 1 .73 1 .89
Mean 281 .7 266 287 .7 282 .7 1 .44 1 .81 1 4 172
SE 6.6
8.5
14
.9 9.1
0 .13
0.11 0 .13 007
IAOC Val . 19, n.. I
bath PM:118-2r
or-.w ntd. a ... r.&1
Figure 1 . Mean procainamide blood level in the 15 patients during
the five infusion periods. The error burs denote standard error .
Figure S
. Amerograde accessory pathway effective refrac-
tory period and Mock cycle length increased to a greater
extent than retrograde accessory pathway effective refrac-
tory period and block cyck length (interaction term p = 0 .03
fog both effective refractory period and block cycle length)
.
Concentrations of procainamide resulting in 5th
prolonga-
tion
of anterograde and rdrvpaade measurements (EC,,I
could be calculated in I I patients. In three patients, antere-
grade and retrograde ECro measurerrnnts coed rat be
dete pined because prexinamide had insufficient effects on
both anterograde and retrograde accessory pathway refrac-
toriness. In one patient, anterograde EC,,, measurements
could be determined, but procainamide had an insuScient
affect on retrograde refractoriness to allow retrograde EC
w
measurements to be determined .
FIfoee4. Mean blood pressure (BP) and sinus cycle length
(ml) during procainamide infusion. There were significant
decreases in both sinus cycle lend; tp < 0.001) and mean
blood pressure (p < 0A01). The error bars denote standard
error .
Ion
non
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prnenln.mide date level
Figure 5. Changes in accessory pathway effective refractory period
(upper pond) and black cycle kngth linear pod) during procrina-
mide infusion . The anterograde refractory period and block cycle
length increased to a greater extent than did the retrograde refrac-
tory period and block cycle length (both p = 0 .031.
In the remaining II patients, the EC, value for the
anterograde accessory pathway effective refractory period
was less than the EC ro
value for the retrograde accessory
a
no
70
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Masot 6. Kaplalt•M eier plot for probability of persistence of acces-
sory pathway conduction
in the anteronrade f • . . ) and retrograde
(-) directions. The diBercnec between antarpgrade and relro-
grade accessory pathway conduction was significant (p = 0.04)
•
pathway refractory period (27 .3 [log - 4
.56 '- 0 . i31 vs. 64.6
1-4,19 ± 0.111 pmoldliter, respectively, p = 0
.02) (Table 1) .
Similarly, ECre
for accessory pathway block cycle length in
rolls
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theanterogadedirection
(25,11-4.6
.
O.I31 anioUliter)was
less than in the
retrograde
direction (52 .5 1-4,28 a 0.071
penopfiter. p = O.Oq . For all 15 patients . the probability of
persistence of accessory pathway conduction in the antero-
grade direction was less than in the retrograde direction (p =
004) Mg, 61. By the 3rd dose level, anterogade pre-
excitation was no longer present in six patients, whereas
retrograde conduction over the accessory pathway did not
disappear in any patient
. In no patient was retrograde
accessory pathway conduction abolished before anterograde
accessory pathway conduction .
Discussion
Prrcaiwmlde
effect an nnhrograde veia
retrograde ow
duclion. This study demonstrates that intravenous procain
.
amide exerts a greater effect on anterogade than an retro-
grade accessory pathway refroctminess . This differential
effect implies that changes in anterograde pre-excitation
after procainamide do not predict the therapeutic effect of
the drug in
preventing orthodromic AV reentry . In some
instances, induction of orthodramic AV reentry may even be
facilitated by procainamide (Fig . 7). This phenomenon can
occur if there is marked prolongation of anterograde a=s-
scary pathway refractoriness without concomitant changes in
retrograde accessory pathway refractoriness. In combine-
Flgere 7. Example of proarrhythmia during
prucainamide infusion
. A. At baseline, during
atrial incremental racing, amegrade aeoes-
snry pathway conduction persisted to a cycle
length of w250ms. Orthodramic reciprocating
wchycasdia was not imiucible by atria] stim-
ulation . O . At the third pmeeinamtde dose,
anterograde accessory pathway conduction
blacks at a cycle length of 400 ms
. but retry
grade accessory pathway condtetion
is only
minimally affected
. Onhodromic atrioventric-
ularrachycardia utilizing the k8 lateral aces •
nary pathway as the retrograde limb is in-
duced by atrial pacing after aaterograde
accessory pathway conduction blocks . CSd =
distal surtmary sinus; CSp = proximal coro-
nary sinus : HOE = His bundle electrugmm :
HRA = high right atrium; RVA = right ven-
Incular apex .
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lion with the vagolytic effect of procainamide . the net result
may be to facilitate induction of tachycardia (2-51 . This
mechanism may explain the reports (4,9,10) of incessant
tachycardia and proorrhythmia after procainamide in pa-
tients with the WotlT Parkinson-White syndrome .
Masaremeniofaccemarypathwayconduction . Threedif-
ferent approaches to the measurement of the effect of
proeanamide on the accessory pathway were used in this
study . These were I) measurement of absolute change in
accessory pathway variables (Fig. 5): 21 measurement of
proportional changes in accessory pathway variables by
curve-modeling techniques (Fig
. 2) ; and 3) estimation of the
probability of accessory pathway conduction by Kaplan-
Meier analysis (Fig. hi. This latter analysis was performed
because of the technical limitations of measuring antero-
grade and retrograde accessory pathway refractoriness at
electraphysiologie study
. The Kaplan-Meiee analysis re-
quired only an assessment of the presence or absence of
accessory pathway conduction
. which could be determined
in all patients at each drug level . This analysis demonstrated
important qualitative differences in the response of the
accessory pathway, which were confirmed by the absolute
changes in accessory pathway measurements
. The results
from curve modeling of the individual dose-response curves
allowed some quantitative estimate of the differential effect
of procainamide- It is important to note that all three
approaches yielded congruent results,
Possible mechanisms far the differential effect of proraina-
dIe . Several observations suggest that there are funda-
mental differences between anterograde and retrograde ac-
cessory pathway conduction and that the safety margin for
conduction in the retrograde direction is higher than that in
the anterograde direction . Unidirectional retrogradely con-
ducting pathways have been found far more frequently than
have unidirectional anterogradely conducting pathways(11) .
Spontaneous loss of pre-encitation has also been reported
(12) with continued retrograde accessory pathway conduc-
tion . One report (13) of accessory pathway ablation sug-
gested that it may be easier to abolish anterograde than
retrograde accessory pathway conduction with direct cur-
rent ablation
. Finally, in a large series of patients (141 . there
was only a weak relation between anterograde and rctro-
grade accessory pathway block cycle lengths . Differences
between anterograde and retrograde conduction might result
from accessory pathway geometry with anisatropic conduc-
tion (15). discontinuous propagation
(t6) and -impedance
mismatch" (17-19) . Evidence against this latter hypothesis
has been presented in an airial myocardial model of acces-
sory pathways (19) . In that model, procainamide did not
exert a differential efiecL an bidirectional conduction ; how-
ever, there may be substantial differences between the
model and actual accessory AV pathways.
Alternatively, the observations in this study could he
explained by the presence of closely separated multiple
accessory pathways or branching networks of fibers (14,20)
In some patients . A second concealed accessory pathway
LEITCH ET AL .
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might continue to conduct after a bidirectional pathway had
blacked . Although patients with clearly demonstrable mul-
tiple accessory pathways were excluded from this study, the
techniques used did not have sufficient resolution to demon-
strate discrete but closely located (I to 2 coal accessory
pathways . Observations during radiofrequency ablation sug-
gest that closely separated accessory pathways may occur
relatively often (20).
At baseline, the anterograde accessory pathway refrac-
tory period leaded to be longer than the retrograde acces .
sory pathway refractory period, although this did not
achicse statistical significance . Because the response of an
accessory pathway to procainamide may depend on the
initial refractory period
(5), the differential response may
also reflect differences in anterograde and retrograde acces-
sory pathway conduction and refractoriness at baseline.
Limitations of the Judy. Exact measurements of acces-
sory pathway refractory period and block cycle length could
not he made in all patients . Retrograde accessory pathway
refractory period measurements were made on the tight
ventricular electrogrem, which may have slight! ; overesti-
mated differences between anterograde and retrograde mea-
surements as a result of ventricular conduction delay . This
factor would not affect the measurement of accessory path-
way block cycle length
. There were significant decreases in
blood pressure and sinus cycle length during the procaine •
mide infusion, in keeping with the known vasodilator and
vagolytic properties of the drug (21).
These autonomic
changes may have modulated the direct effects of procaina-
mide on the accessory pathway (22-24)
. Our study also had
a relatively small sample size and did not include patients in
whom retrograde accessory pathway conduction was not
clearly distinguishable from normal ventriculoarial con,
duction
. Therefore, these findings may not apply to all
patients with the Wolll Parkinson-White syndrome . Finally,
it is possible that our results would not be
replicated with
oral procainamide because of the actions of its metabolite,
N-acetyl procainamide .
Nonetheless, these data demonstrate a systematic differ-
ential effect of procainamide on anterograde and retrograde
accessory pathway refractoriness. The greater margin of
safety for retrograde conduction after procainamide may
influence drug selection, depending en the mechanism of the
symptomatic arrhythmia .
we dunk Sheila Duo, for preparation of sire masNSCrwt-
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